

1    **Supplementary Information**

2    **Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and**

3    **other respiratory viruses**

4    Ming Wang<sup>#1</sup>, Aisi Fu<sup>#2</sup>, Ben Hu<sup>#2</sup>, Yongqing Tong<sup>#1</sup>, Ran Liu<sup>#2</sup>, Jiashuang Gu<sup>3</sup>, Jianghao Liu<sup>3</sup>,

5    Wen Jiang<sup>3</sup>, Gaigai Shen<sup>2</sup>, Wanxu Zhao<sup>2</sup>, Dong Men<sup>4</sup>, Zixin Deng<sup>1,5,6</sup>, Lilei Yu<sup>7</sup>, Yan Li\*<sup>1</sup>,

6    Tiangang Liu\*<sup>2,6</sup>

7

8    <sup>1</sup> Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060,

9    China

10    <sup>2</sup> Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education and

11    Wuhan University School of Pharmaceutical Sciences, Wuhan, 430071, China

12    <sup>3</sup> Wuhan Dgensee Clinical Laboratory Co., Ltd., Wuhan, 430075, China

13    <sup>4</sup> Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei Province, P.R. China

14    <sup>5</sup>State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of

15    Metabolic & Developmental Sciences, and School of Life Sciences and Biotechnology, Shanghai

16    Jiao Tong University, Shanghai, 200030, China

17    <sup>6</sup>Hubei Engineering Laboratory for Synthetic Microbiology, Wuhan Institute of Biotechnology,

18    Wuhan, 430075, China


19    <sup>7</sup>Department of Internal Medicine, Renmin Hospital of Wuhan University, Wuhan, 430060, China

20    # These authors contributed equally to this work.

21    ***Corresponding author:***

22    Tiangang Liu, ([liutg@whu.edu.cn](mailto:liutg@whu.edu.cn)) ; Yan Li, ([yanlitf1120@163.com](mailto:yanlitf1120@163.com))

23



24

25 **Supplementary Fig. 1| Performance verification test of NTS for detecting SARS-CoV-2 using**  
 26 **standard synthetic S and N genes.** Comparison of all SARS-CoV-2 reads detected by NTS in  
 27 replicates with different concentrations and negative controls using 30 min (a), 2 h (b), or 4 h  
 28 (c)sequencing data. Read counts mapped to each target region of the SARS-CoV-2 genome in  
 29 replicates with different concentrations with 30 min (d), 2 h (e), or 4 h (f) sequencing data. Two-  
 30 tailed Student t-test (for normal distribution samples) or Mann–Whitney U-test (for non-normal  
 31 distribution samples): ns, not significant,  $*P < 0.05$ ; bars represent the means  $\pm$  SD.

**a**

Patient ID	RdRP	NTS target sites										Final result of NTS and qPCR			
		S1	S2	S3	S4	S5	S3a	3aM	M7a	7aN	N	N10	NTS Score	NTS	qPCR
A2	10	5	11	6	10	1	1	3	5	5	19	0	5	Pos	Pos
A4	65	66	80	70	62	6	14	17	29	91	174	1	9.8	Pos	Pos
C1	237	168	199	157	184	17	54	50	203	212	267	23	11.4	Pos	Pos
C2	141	142	267	134	200	4	73	21	83	224	219	34	10.8	Pos	Pos
D12	375	262	373	226	352	42	165	75	187	428	257	12	11.4	Pos	Pos
E5	15	22	32	14	17	0	9	2	10	35	43	0	7.4	Pos	Pos
G1	156	60	134	116	97	9	42	27	99	184	226	4	10.2	Pos	Pos
H9	164	212	279	170	252	14	73	53	179	200	315	1	10.4	Pos	Pos
E1	44	31	18	16	17	3	2	4	30	29	33	0	7.8	Pos	Pos
A6	0	2	1	0	0	1	1	0	0	0	0	0	0	Neg	Inc
A9	1	0	3	0	0	0	0	1	2	8	5	0	0.8	Neg	Inc
A12	0	0	0	0	1	0	0	0	1	0	12	0	0	Neg	Inc
B4	0	0	0	0	0	0	0	0	0	1	1	0	0	Neg	Inc
C11	0	0	0	0	2	0	0	0	0	0	4	0	0	Neg	Inc
D2	0	0	0	0	0	0	0	0	0	0	1	0	0	Neg	Inc
F5	17	21	0	10	0	0	0	0	0	0	1	0	3	Pos	Inc
F12	1	0	0	0	0	0	0	0	0	0	0	0	0	Neg	Inc
H12	0	3	2	0	0	0	0	0	0	0	1	0	0.4	Neg	Inc
D10	0	0	0	1	0	0	0	0	0	0	0	0	0	Neg	Inc
A1	1	0	1	0	0	0	1	1	0	1	0	0	0	Neg	Neg
A3	1	1	0	0	0	0	0	0	0	0	0	0	0	Neg	Neg
A5	0	0	0	0	0	0	0	0	0	0	3	0	0	Neg	Neg
A7	0	0	0	0	0	0	0	0	0	4	70	3	0.8	Neg	Neg
A8	0	0	0	0	0	0	0	0	0	0	1	0	0	Neg	Neg
PC	0	58	44	40	49	28	4	0	0	0	0	0	5.4	Pos	Pos
NC	0	0	0	0	0	0	0	0	0	0	34	0	NA	Neg	Neg
A11	8	0	0	4	1	0	0	0	0	48	18	0	2.8	Pos	Pos
B9	106	9	40	65	18	1	41	4	9	65	75	4	8.6	Pos	Pos
C9	81	8	37	7	37	0	0	2	11	92	4	0	6.2	Pos	Pos
D9	65	18	111	50	53	6	55	5	5	156	127	0	9.2	Pos	Pos
D11	23	18	38	3	32	0	25	0	11	33	61	0	8.4	Pos	Pos
E3	1	0	4	3	7	0	0	0	0	0	5	0	1.6	Inc	Pos
E11	16	10	44	23	16	0	38	5	5	51	70	6	9.2	Pos	Pos
F11	114	37	82	78	23	4	96	9	16	116	132	0	9.8	Pos	Pos
G11	205	124	181	117	140	3	142	33	40	215	181	1	10.4	Pos	Pos
G12	255	70	302	86	90	0	218	3	96	375	65	0	9.4	Pos	Pos
C12	3	6	10	0	0	0	5	1	3	4	2	0	3	Pos	Inc
E6	6	11	21	0	0	0	0	1	0	0	0	0	2.4	Inc	Inc
E12	0	0	0	1	0	0	0	0	0	0	0	0	0	Neg	Inc
F8	0	8	0	0	18	0	0	0	0	6	0	0	1.8	Inc	Inc
G6	0	0	14	0	0	0	1	0	0	0	0	0	1	Neg	Inc
H3	0	0	1	4	0	0	0	0	0	0	0	0	0.4	Neg	Inc
A10	0	0	0	0	0	0	0	0	0	0	2	0	0	Neg	Neg
B1	1	0	0	0	0	1	0	0	0	1	2	0	0	Neg	Neg
B2	0	1	0	0	1	0	0	0	0	3	0	0	0.4	Neg	Neg
B3	1	6	1	0	4	1	0	0	0	11	19	0	2.8	Pos	Neg
B5	0	0	0	0	0	0	0	0	0	0	0	0	0	Neg	Neg
PC	0	48	57	39	52	28	1	0	0	0	0	0	5	Pos	Pos
NC	0	0	0	0	0	0	0	0	0	0	0	0	NA	Neg	Neg

**b**

Patient ID	RdRP	NTS target sites										Final result of NTS and qPCR			
		S1	S2	S3	S4	S5	S3a	3aM	M7a	7aN	N	N10	NTS Score	NTS	qPCR
R01	0	0	1	0	0	0	1	0	0	0	0	0	0	Neg	Pos
R02	0	0	1	0	1	0	0	0	0	1	0	0	0	Neg	Neg
R03	2	0	2	0	0	0	0	0	0	0	2	0	0	Neg	Pos
R04	0	0	0	0	0	0	0	0	0	0	0	0	0	Neg	Neg
R05	3	0	4	2	0	0	15	0	5	29	19	0	4.2	Pos	Pos
R06	6	0	3	1	0	0	3	0	0	1	9	0	1.6	Inc	Inc
R07	0	0	0	0	2	1	0	0	0	0	1	0	0	Neg	Inc
R08	1	0	0	0	0	0	0	0	0	0	0	0	0	Neg	Inc
R09	0	1	0	0	0	0	1	0	0	0	0	1	0	Neg	Neg
R10	1	0	5	0	1	0	0	0	0	0	0	1	0.4	Neg	Neg
R11	335	26	492	62	155	0	317	7	14	286	300	4	9.8	Pos	Pos
R12	34	7	47	2	2	0	16	0	0	44	19	0	5.4	Pos	Pos
R13	3	0	0	0	0	0	13	0	0	2	0	0	1.4	Inc	Pos
R14	0	0	1	0	0	0	0	0	0	0	1	0	0	Neg	Pos
R15	0	1	9	0	3	0	6	0	0	6	3	0	2	Inc	Pos
R16	1	0	1	0	0	0	0	0	0	0	0	0	0	Neg	Pos
NC	0	0	0	0	0	0	0	0	0	0	0	0	NA	Neg	Neg
NC	0	0	0	0	0	0	0	0	0	0	0	0	NA	Neg	Neg

Positive
Inconclusive
Negative

33 **Supplementary Fig 2. Comparison of 61 nucleic acid sequences from clinical samples obtained**  
34 **using NTS (10 min) and qPCR.** **a**, Comparison of 45 nucleic acid sequences from samples of  
35 patients with suspected COVID-19 obtained using NTS and qPCR (kit 2). **b**, Comparison of 24  
36 nucleic acid sequences from patients with confirmed disease obtained using NTS and qPCR (kit1).  
37 The numbers in the table on the left represent the number of mapped reads according to our rules.  
38 PC: positive control. The plasmid harboring an *S* gene was used as a positive control in NTS  
39 testing; a positive sample in the kit served as a positive control in qPCR testing. NC: negative  
40 control. Tris-EDTA buffer was used as a negative control in NTS testing; H<sub>2</sub>O in the kit served as a  
41 positive control in qPCR testing. Pos: positive. Inc: inconclusive. Neg: Negative.  
42

43      **Supplementary Table 1. Primers for amplification of specific fragments of SARS-CoV-2 in**  
 44      **NTS**

Primer	Primer sequence
S1-F	TTGTTTTCTTGTAAATTGCCACT
S1-R	ACCAATGGTTCTAAAGCCGA
S2-F	TCACTAGGTTCAAACTTACTTGC
S2-R	TTACAAGGTGTGCTACCGGC
S3-F	TGGTGTTGAAGGTTAATTGTTAC
S3-R	ACTAGCTACACTACGTGCC
S4-F	CAATCCATCATTGCCTACACTAT
S4-R	AAGCGTGTAAAGCTTGTGC
S5-F	GTTAACAACTTAGCTCCAATTG
S5-R	CAGCCCTTGAGACAACTACAG
S3a-F	GTTCTTGTGGATCCTGCTGCAAAT
S3a-R	TTAACAACTCCGGATGAACCGT
3aM-F	TCCAGTAATGGAACCAATTATGA
3aM-R	TGAATGACCACATGGAACCG
M7a-F	ATCCAGAAACTAACATTCTTC
M7a-R	GATAGACGTGTTACGCCG
7aN-F	AGTTACGTGCCAGATCAGT
7aN-R	ATGTTGAGTGAGAGCGGTGA
N-F	GGCAAGGAAGACCTTAAATTCC
N-R	CCCGAAGGTGTGACTTCAT
N10-F	AACGTGGTTGACCTACACAG
N10-R	TCCAAGTCAAGAACACAGGATT
Orf1ab-F1	TATGCCATTAGTGCWAAGAATAGAG
Orf1ab-R1	CARATGTTAAASACACTATTAGCATA
Orf1ab-F2	ACTATGACCAATAGACAGTCATC
Orf1ab-R2	ATTGGCCGTGACAGCTTG

46 **Supplementary Table 2. NTS score and positive detection rate of 10 copies standard plasmids**  
47 **at different time**

Time	NTS score				Positive number	Inconclusive number	Negative number
	1	2	3	4			
10 min	0	0.4	0	0.4	0	0	4
30 min	1	1.8	0	0.4	1	1	2
1 h	1.4	2.4	0.4	2	3	0	1
2 h	1.4	3.8	0.4	2.4	3	0	1
4 h	3	3	1.2	3	3	1	0

**Supplementary Table 3. Target of amplification of common respiratory viruses in NTS**

Virus	Target gene	Accession number (Region) <sup>a</sup>
Bocavirus	<i>NPI</i>	MK034749.1 (2351-2704)
Bocavirus	<i>VP1-2</i>	MK034749.1 (4370-5189)
Rhinovirus	Polyprotein gene	MK032898.1 (145-541)
Human metapneumovirus	<i>N</i> gene	MN745087.1 (82-521)
Human metapneumovirus	<i>F</i> gene	MN745087.1 (3678-4425)
Respiratory syncytial virus	<i>G-F</i> gene	KF246618.1 (1237-1768)
Respiratory syncytial virus	<i>G-F</i> gene	MH760613.1 (5776-6357)
Respiratory syncytial virus	<i>N-P</i> gene	MK733768.1 (1673-2510)
Coronavirus	<i>orf1ab</i>	HM211099.1 (14699-15761)
Coronavirus	<i>orf1ab</i>	MN310478.1 (14883-15565)
Adenovirus	hexon	MH910668.1 (20146-21023)
Adenovirus	hexon	MH910668.1 (21029-21146)
Parainfluenza virus	<i>H</i> gene	AB641312.1 (355-830)
Parainfluenza virus	<i>H</i> gene	MK167042.1 (4269-5205)
Parainfluenza virus	<i>H</i> gene	MH678693.1 (7468-7945)
Influenza A virus	<i>M</i> gene	MT031658.1 (12-581)
Influenza B virus	<i>M</i> gene	MT056023.1 (1-414)
Influenza B virus	<i>HA</i> gene	MT057835.1 (20-494)
Influenza B virus	<i>NA</i> gene	MT057837.1 (713-1464)
Influenza C virus	<i>M</i> gene	MK480600.1 (1- 1052)

49      <sup>a</sup> Select a sequence in GenBank as the representative of the amplification area selected in NTS.

50      Accession number represent the number in GenBank, the position marked in parentheses refers to  
 51      the position of the sequence in the accession number. This region is the target region for  
 52      amplification.

54 **Supplementary Table 4. Detail of respiratory viruses primers panel**

Virus	primer	Sequence
Bocavirus	BCV-F1	GASCTCTGTAAGTACTATTRC
	BCV-R1	CTCTGTGTTKRCTGAATACAG
	BCV-F2	GGACCACAGTCATCAGAC
	BCV-R2	CCACTACCATCGGGCTG
Rhinovirus	HRV-F1	CAAGCACTTCTGTYWCCCC
	HRV-R1	ACGGACACCCAAAGTAG
	HRV-F2	CAAGCACTTCTGTTCCC
	HRV-R2	GAAACACCCAAAGTAG
Human metapneumovirus	HMPV-1	AAGCATGCTATATTAAAAGAGTCTCA
	HMPV-2	ATTATGGGTGTGTCGGTGCTGA
	HMPV-3	CAATGCAGGTATAACACCCAGCAATATC
	HMPV-4	GCAACAATTGAACTGATCTTCAGGAAAC
	HMPV-5	CCTTTATAACATGCTGTTACC
Respiratory syncytial virus	RSV-F1	ATGATTWYCAYTTGAAGTGTTC
	RSV-F2	GGTTGGTATACCACTGTCATAAC
	RSV-R1	TGTTCTTGTGGAAYTCTATCACAG
	RSV-R2	AGTTACACCTGCATTAACACTAAATT
	RSV-F3	GTCTTACAGCCGTGATTAGG
	RSV-R3	GGGCTTCTTGGTTACTTC
Coronavirus	HCoV-R1	TTRTARCANACAAACNSCATCATCA
	HCoV-R2	GCATWGTRTGYTNGARCARAATT
	HCoV-F1	ACWCARHTVAAYYTNAARTAYGC
	HCoV-F2	GGWTGGGAYTATCCYAAARTGTGA
	HCoV-F3	GGWTGGGAYTATCCYAAARTGTGAT
	HCoV-R3	CCCCATCATCASWVARAATCATCAT
	HCoV-R4	CCCCATCATCASWVARAATCATCATA
	HCoV-F4	ACTCARWTRAATYTNAATAYGC
Adenovirus	AdV-F1	TTCCCCATGGCNCACAAAYAC
	AdV-F2	GCCACCTTCTCCCCATGGC
	AdV-F3	AGACATGACHTTYGAGGTGGAYCC
	AdV-R1	GTGCGGCTGGTGCACACCGA
	AdV-R2	GTAGCGTTGCCGGCCGAGAA
	AdV-R3	GTAGCGTTGCCGGCCGAGAAG
Parainfluenza virus	HPIV-F1	CYTAAATTCAAGATATGTAT
	HPIV-F2	CYTAAATTCAAGATATGTATCCTG
	HPIV-R1	GATAAATAATTATTGATAYG
	HPIV-R2	TCAGATAAATAATTATTGATA
	HPIV-F3	AACAATCTGCTGCRGVRTTT
	HPIV-F4	ATACAACAATCTGCTGCRGV
	HPIV-R3	ATGTCAGAYAATGGRCAAAT
	HPIV-R4	GTCAGAYAATGGRCAAATAAG

	HPIV-F5	CTGTAAACTCAGAYTTGGTA
	HPIV-R5	TTYAARCCYTTGTCAACAAAC
	HPIV-F6	CCGGTARTTCYCATAACCTATG
Influenza A virus	IAV-R1	CCAGCCATCTGYTCCATAGC
	IAV-R2	GTRGTGCTRGCAGCACC
	IAV-F1	ARATGAGYCTTCTAACCGAGGTCG
	IAV-F2	AGGGCATTGGACAAAKCGTCT
Influenza B virus	IBV-F1	ATGTCGCTGTTGGAGACACAAT
	IBV-R1	TCAGCTAGAACATCAGRCCYTTCTT
	IBV-4	CCAGGATTCAAGGTACATGACC
	IBV-F2	ATGAAGGCAATAATTGTACTACTC
	IBV-R2	GGCAAGAYCCTGAGGTTCC
	IBV-F3	CAAGAAAGTGCCTGCAATTGC
Influenza C virus	ICV-F1	GTTGCTCCTGAGACCAGGACAG-
	ICV-F2	GAATCACACACCAGACATCCG
	ICV-R1	GAGTTGTCGGTTCTGTCAG
	ICV-F3	ACAGCTTGGTTRAGATGCAA

55

56

57    **Supplementary Table 5. the result of NTS for detection of respiratory viruses in mixed clinical**  
58    **sample**

Respiratory viruses	Detected reads (10 mins)	Detected reads (2h)
influenza A virus	2	80
influenza B virus	2	34
parainfluenza	ND	8
respiratory syncytial virus	354	4378
rhinovirus	61	702

59    ND: not detected.

60

61

62